JBA AI Earns FDA SaMD Recognition
GARDEN GROVE, CALIFORNIA / ACCESS Newswire / June 9, 2025 / JBA AI, the flagship health-tech division under AQ Pharmaceuticals, Inc. and JBA Brands, proudly announces several major global milestones in its mission to make preventive healthcare more accessible, intelligent, and affordable.JBA AI Infographic
JBA AI has been officially recognized by the United States Food and Drug Administration (FDA) as a Software as a Medical Device (SaMD). In addition, the platform has now received Class B Medical Device approval from Vietnam's Ministry of Health. These achievements affirm the platform's safety, clinical effectiveness, and international credibility.
The JBA AI mobile application is already available globally for Android users and will soon be released on iOS. It enables contactless, non-invasive vital signs monitoring directly through smartphones or tablets. In just 60 seconds, the app delivers insights on over nine key health metrics. These include heart rate, heart rate variability, blood oxygen saturation, respiratory rate, stress index, and estimated glucose and blood pressure trends. This is achieved using AI-powered facial signal analysis through camera-based remote photoplethysmography technology.
Expanding its impact even further, JBA AI has partnered with one of Vietnam's largest financial institutions, which serves more than 30 millions members. Together, they are preparing to launch JBA AI nationwide, making preventive health monitoring more accessible through a trusted and widespread digital network.
'JBA AI is more than a health app - it's a certified medical device. Recognized by both the FDA and Vietnam's Ministry of Health,' said Tracy Trang Nguyen, founder and CEO of JBA AI. 'We're proud to deliver trusted, clinically guided tools for daily health monitoring worldwide.'
Nguyen is a Vietnamese American engineer and wellness industry leader who developed JBA AI after surviving cancer. Her personal health journey inspired her to combine advanced artificial intelligence with affordable wellness solutions. Under her leadership, JBA AI complements other products within the JBA Brands portfolio, such as GlucoTrojan, Joint Revive Fucoidan, and Vegan Collagen, to form a fully integrated health ecosystem.
JBA AI is already gaining traction and is starting to expand into pharmacies, corporate wellness programs, public health campaigns, and family clinics across the United States, Vietnam, and other countries. The platform's franchise-ready model supports rapid local deployment while keeping costs low and impact high. It is designed to help people monitor their health in real-time, without the need for needles, wearable devices or clinic visits.
JBA AI is currently welcoming franchisees, affiliates, and institutional partners to help bring this technology to communities around the world. Whether at home or in partnership with healthcare providers, JBA AI is redefining preventive care through data-driven technology and a compassionate approach to well-being.
Contact Information
Catherine Marino
Marketing Manager
[email protected]
(+1) 714 903 1009
SOURCE: AQP One, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 hours ago
- Forbes
Oscar Health: Should You Buy OSCR Stock At $17?
CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Oscar Health, Inc. is displayed ... More on a smartphone screen, with the company's branding visible in the background, on May 04, 2025, in Chongqing, China. (Photo illustration by) On July 2nd, the health insurance sector underwent a notable decline following Centene (NYSE:CNC)'s retraction of its financial outlook, citing rising costs. Refer to – Centene: Is The Recent Decline In CNC Stock Justified? This announcement caused turmoil in the market, leading to a 40% plunge in Centene's stock. Other significant players also faced considerable declines: Oscar Health (NYSE: OSCR) decreased by 19%, UnitedHealth (NYSE: UNH) dropped 6%, Molina (MOH) fell 22%, and CVS (CVS) saw a decrease of 4%. The primary issue confronting these insurers is a legitimate one: increasing medical costs are diminishing their profits. This rise in expenses is due to various factors, including a higher number of less healthy individuals enrolling, an uptick in the volume of medical procedures, and persistently high prices for drugs. Given these industry-wide difficulties, a critical question for investors is whether Oscar Health's stock, currently priced around $17, represents a buying opportunity. Although OSCR has risen 23% year-to-date, it is still trading 30% below its 52-week peak of over $23. We believe that OSCR stock represents a solid choice at its current price of $17. Our conclusion is drawn from a thorough analysis of Oscar Health's current valuation in relation to its recent operational performance as well as its historical and present financial health. Our detailed evaluation of Oscar Health emphasizes essential factors: Growth, Profitability, Financial Stability, and Downturn Resilience. Our analysis reveals that the company has moderate operational performance and financial condition, yet its current valuation is appealing, which we explain in more detail below. However, for those seeking upside with lower volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — having outperformed the S&P 500 and delivering returns exceeding 91% since its launch. Separately, refer to – UnitedHealth: Buy Or Sell UNH Stock At $325? How Does Oscar Health's Valuation Compare to The S&P 500? When considering what you pay per dollar of sales or profit, OSCR stock appears slightly undervalued in relation to the broader market. How Have Oscar Health's Revenues Evolved in Recent Years? Oscar Health's Revenues have increased significantly over the past few years. How Profitable Is Oscar Health? Oscar Health's profit margins are significantly lower than most companies within the Trefis coverage universe. Is Oscar Health Financially Stable? Oscar Health's balance sheet appears quite robust. How Resilient Is OSCR Stock During A Downturn? OSCR stock has performed significantly worse than the benchmark S&P 500 index during several recent downturns. As investors hope for a gentle landing by the U.S. economy, how severe could the situation be if another recession occurs? Our dashboard How Low Can Stocks Go During A Market Crash shows how crucial stocks performed during and after the last six market crashes. Summarizing the Findings: Implications for OSCR Stock In conclusion, Oscar Health's performance across the previously mentioned criteria is as follows: In summary, Oscar Health has shown a moderate performance across the essential criteria of Growth, Profitability, Financial Stability, and Downturn Resilience. Although its profit margins seem modest compared to the broader market, this is common for the health insurance sector, which generally operates on thin margins and high volumes. This industry-wide trait is also reflected in valuation standards. For example, Centene and CVS trade at 0.2 times their revenue, Molina at 0.4 times, and UnitedHealth (UNH) at 0.7 times. Despite these industry standards, we contend that Oscar Health's technological framework and robust revenue growth justify a higher valuation multiple than that of several more traditional insurance competitors. Overall, we consider it a solid choice at present levels. However, it is crucial to recognize potential risks. Investors may be reluctant to assign a higher multiple due to the naturally slim margins in the industry and the stock's volatility. Thus, investors should carefully assess these risks before making a decision to invest in Oscar Health. There always exists a significant risk when investing in a single stock, or merely a few. Consider Trefis High Quality (HQ) Portfolio which, comprising 30 stocks, has a history of consistently outperforming the S&P 500 over the last 4-year span. What accounts for this? Collectively, HQ Portfolio stocks yielded superior returns with reduced risk compared to the benchmark index; less of a roller-coaster experience, as evidenced in HQ Portfolio performance metrics.
Yahoo
3 hours ago
- Yahoo
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
New benchmark confirms LENSai's ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. AUSTIN, Texas, July 03, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA's patented HYFT® technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. "It's generally assumed that AI can only make accurate predictions if it has seen similar data before," said Dr. Jennifer Bath, CEO of ImmunoPrecise. "But this benchmark proves otherwise: LENSai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. And the predictions aligned with wet-lab results. This is a major breakthrough in generalizing AI for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. It shows that AI doesn't always need massive data to be powerful and accurate - it just needs the right kind." LENSai Epitope Mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins - helping scientists design better treatments faster. Unlike traditional methods that take months and require lab work, LENSai delivers results in hours - using just the digital sequences - cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments. In a new benchmark study, LENSai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. Despite having no prior exposure to these molecules, LENSai achieved prediction scores nearly identical to those from its original training data. This score, known as AUC (Area Under the Curve), is a widely accepted measure of accuracy in computational biology. The consistent performance on entirely new, unseen complexes confirms that LENSai's artificial intelligence can reliably analyze and predict antibody binding - even for molecules outside its training set. This breakthrough demonstrates LENSai's power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery. Why This Benchmark Matters In the new study, LENSai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples - proving true generalization, not memorization. Because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays. What It Means for Partners and Investors With LENSai already embedded in collaborations across big pharma and biotech, ImmunoPrecise is scaling access through secure APIs and custom partnerships. The platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets - positioning the company and its investors at the forefront of AI-driven antibody therapeutics. For more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of LENSai Epitope Mapping. The first highlights performance on a "seen" target, where the system was trained on related data. The second - featured in this press release - demonstrates LENSai's breakthrough ability to accurately map binding sites on a completely "unseen" target, with no prior exposure to the antibody, the antigen, or their structure. New Case Study: LENSai Epitope Mapping on an "Unseen" Target [link] Previous Case Study: Head-to-Head Benchmark on a "Seen" Target [link] These examples underscore how LENSai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," or similar expressions, or by statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. These statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the LENSai™ and HYFT® platforms; the generalizability of the Company's AI models to novel therapeutic targets; the role of AI in accelerating antibody discovery; and the Company's future scientific, commercial, and strategic developments. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological innovation, risks related to model validation and generalizability in real-world settings, intellectual property protection, strategic partner adoption, regulatory pathways, and market demand for AI-driven therapeutic platforms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. View source version on Contacts Investor Relations Contact Louie TomaManaging Director, CORE IRinvestors@ Sign in to access your portfolio
Entrepreneur
4 hours ago
- Entrepreneur
Luma Fertility, FitFeast Raise Seed Capital to Redefine Reproductive Care and Protein Consumption
The below brands have announced their latest funding rounds. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Luma Fertility Raises USD 4 Mn Seed Funding Luma Fertility, a patient-centric and tech-enabled fertility startup, has secured USD 4 million in seed funding led by Peak XV's Surge, with backing from Ameera Shah of Metropolis Healthcare and Vijay Taparia of B2V Ventures. The funding will support the expansion of Luma's full-stack fertility clinics, starting in Mumbai and scaling to other cities over the next two years. Founded by Neha K Motwani in 2023—after her personal struggles with fertility—Luma aims to revolutionise reproductive care in India by prioritising empathy, transparency, and clinical excellence. "Fertility care in India is broken. It's optimised for systems, not people," said Motwani. "At Luma, we've rebuilt it from the ground up—designed entirely around the patient." Luma offers a wide range of services, including IVF, egg and embryo freezing, fertility assessments, pre-conception consults, and at-home semen analysis. Its integrated digital platform includes a proprietary app and LumaAI—an AI-enabled support system for 24/7 cycle guidance. The clinic also offers outcome-enhancing support like nutrition, acupuncture, and emotional wellness sessions. Notably, Luma claims that it is the first IVF clinic in India with a see-through embryology lab and a dedicated care specialist for every patient. Backing Luma's mission is a seasoned team including Chief Embryologist Chirag Shah and Medical Director Dr Radhika Sheth. "What drew me to Luma is their full-stack, customer-first approach," said Ameera Shah. With India's fertility rate declining and demand rising, Luma is poised to redefine fertility care for the modern Indian family. Protein-Focused Nutrition Brand FitFeast Raises INR 5.5 Cr FitFeast, a flavour-first protein brand, has raised INR 5.5 crore in seed funding led by Inflection Point Ventures (IPV), with participation from industry leaders including Raghav Singhal (Founder at Swasthum Wellness), Santosh Govindaraju (Sustainability Executive, Investor and Board Member), Abhishek Chopra and Aabhas Khanna from HSBC. The funds will be used to strengthen FitFeast's digital presence, scale marketing, expand leadership, and launch protein-rich innovations across India and global markets. Founded in 2021 by Aditya Poddar, FitFeast aims to make protein consumption mainstream without compromising on taste. Its offerings include Malai Kulfi protein shakes, dessert-inspired bars, protein chips, and nut butters tailored to Indian palates. "At FitFeast, we're rewriting how India consumes protein—deliciously and accessibly. IPV has believed in that vision from day one," said Poddar. The brand's D2C-first model, supported by platforms like Zepto, Amazon, and Flipkart, delivers across 20,000+ pin codes. FitFeast has already sold over 10 million grams of protein and gained significant traction after appearing on Shark Tank India Season 4. The round also welcomes retired Australian cricketer Shane Watson as an investor and brand partner, joining Indian all-rounder Axar Patel. "After trying FitFeast's chips and shakes, I was genuinely hooked. I believe in this brand for the long run," said Watson. FitFeast has grown 5x in the last four months, now crossing INR 50 lakh in monthly revenue.
